Seres Therapeutics (NASDAQ:MCRB) Share Price Breaks Below Fifty Day Moving Average – Here’s Why

Seres Therapeutics, Inc. (NASDAQ:MCRB) crossed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $3.91 and traded as low as $2.00. Seres Therapeutics shares last traded at $2.09, with a volume of 69,712 shares changing hands.

Analyst Upgrades and Downgrades

Several brokerages recently commented on MCRB. Weiss Ratings cut Seres Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 18th. Wall Street Zen raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $17.00.

Seres Therapeutics Stock Down 1.9%

The company has a market capitalization of $21.00 million, a P/E ratio of -0.86 and a beta of 0.31. The firm’s 50-day moving average price is $3.91 and its 200 day moving average price is $5.82.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.47 EPS for the quarter, topping the consensus estimate of ($2.18) by $2.65. Seres Therapeutics had a negative return on equity of 114.82% and a negative net margin of 1,192.94%. The firm had revenue of $0.74 million during the quarter, compared to the consensus estimate of $0.18 million. As a group, equities research analysts expect that Seres Therapeutics, Inc. will post -6.33 EPS for the current year.

Institutional Trading of Seres Therapeutics

A hedge fund recently bought a new position in Seres Therapeutics stock. Integrated Wealth Concepts LLC bought a new position in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 4,000 shares of the biotechnology company’s stock, valued at approximately $32,000. Institutional investors and hedge funds own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a biotechnology company focused on developing live biotherapeutics designed to restore and maintain the function of the human microbiome. Its research has centered on therapeutic products made from defined mixtures of microorganisms, rather than conventional broad-spectrum antibiotics or nonselective fecal material.

The company’s leading product is VOWST, an orally administered microbiota-based therapy approved by the U.S. Food and Drug Administration for preventing the recurrence of Clostridioides difficile infection in adults following antibacterial treatment for recurrent infection.